Keytruda®

Active substance Pembrolizumab – MK 3475
Holder MSD
Status Closed
Indication Unresectable or metastatic melanoma in patients who are refractory to treatment with ipilimumab
Public documents Approbation
Information for the patient
Informed consent
Last update 07/06/2016
Last updated on 15/09/2023